Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Benefit of Extended Adjuvant Aromatase Inhibition in Breast Cancer Now in Question
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—Extended adjuvant endocrine therapy beyond 5 years with an aromatase inhibitor (AI) failed to improve disease-free survival (DFS) in patients with hormone receptor (HR)-positive breast cancer who were enrolled in the 3 large National Surgical Adjuvant Breast and Bowel Project (NSABP) B-52, IDEAL, and DATA studies, which were presented at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Dual Anti-HER2 Therapy Boosts Progression-Free Survival in Advanced Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—Two HER2-targeted drugs improve progression-free survival (PFS) compared with a single drug when combined with an aromatase inhibitor in patients with advanced breast cancer, as reported at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Hair Preservation Improved by 50% with Investigational Scalp-Cooling Device
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—The use of an investigational electronic scalp-cooling device in patients with breast cancer who had received alopecia-inducing chemotherapy resulted in reduced or no hair loss in 50% of the patients, according to results of a randomized clinical trial reported at the 2016 San Antonio Breast Cancer Symposium. By contrast, no patient in the control group had hair preservation.
Read Article
Good News for a Different Type of CDK4/CDK6 Inhibitor in Early Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—Neoadjuvant therapy with the investigative CDK4/CDK6 inhibitor abemaciclib, alone or in combination with anastrozole (Arimidex), showed promising activity in postmenopausal hormone receptor (HR)-positive, HER2-negative breast cancer enrolled in the phase 2 NeoMONARCH study. Correlative tissue studies demonstrated that abemaciclib inhibited cell-cycle proliferation and activated the immune system, supporting its anticancer activity. Abemaciclib received a breakthrough therapy designation in 2015 as monotherapy for the treatment of patients with refractory HR-positive advanced breast cancer in heavily pretreated patients.
Read Article
Adding Everolimus to Antiestrogen Therapy Doubles Progression-Free Survival in Advanced Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—The addition of the mTOR inhibitor everolimus (Afinitor) to the antiestrogen chemotherapy fulvestrant (Faslodex) led to a 2-fold increase in progression-free survival (PFS) in patients with advanced hormone receptor (HR)-positive breast cancer compared with fulvestrant alone, according to results of a randomized clinical trial presented at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Adding Pembrolizumab to Chemotherapy as First-Line Treatment Significantly Improves Outcomes in Patients with Advanced NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Immunotherapy for advanced non–small-cell lung cancer (NSCLC) took a step toward first-line indication as results from a randomized clinical trial showed that patients who received pembrolizumab (Keytruda) plus chemotherapy had a significantly higher response rate compared with patients who received chemotherapy alone, reported Corey J. Langer, MD, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, at the 2016 European Society for Medical Oncology (ESMO) Congress. The clinical trial results (KEYNOTE-021) were also published in
Lancet Oncology
, and are available online.
Read Article
Immunotherapy with Atezolizumab Outperforms Chemotherapy in Previously Treated NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Immunotherapy competition in non–small-cell lung cancer (NSCLC) continued to heat up as atezolizumab (Tecentriq) improved overall survival (OS) versus docetaxel, according to results from the randomized, phase 3 OAK clinical trial reported at the 2016 European Society for Medical Oncology Congress by Fabrice Barlesi, MD, Professor of Medicine, Aix-Marseille University, France.
Read Article
Ceritinib, a Newer ALK Inhibitor, Improves Progression-Free Survival After Crizotinib Failure in NSCLC
By
Charles Bankhead
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Patients with heavily pretreated
ALK
mutation and non–small-cell lung cancer (NSCLC) had significant improvement in progression-free survival (PFS) after receiving the next-generation ALK inhibitor ceritinib, according to results from the ASCEND-5 study reported at the 2016 European Society for Medical Oncology Congress by Giorgio Scagliotti, MD, Professor of Respiratory Medicine, University of Torino, Italy.
Read Article
Pembrolizumab Succeeds, Nivolumab Fails, as First-Line Therapy for Advanced NSCLC
By
Phoebe Starr
Lung Cancer
,
Solid Tumors
November 2016, Vol 7, No 10
Copenhagen, Denmark—Patients with non–small-cell lung cancer (NSCLC) who lack targetable
EGFR
or
ALK
mutations typically receive platinum-based doublet chemotherapy as first-line therapy. Two phase 3 clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress compared immunotherapy and platinum-based chemotherapy as first-line treatment for patients with NSCLC. In KEYNOTE-024, pembrolizumab (Keytruda) was superior to chemotherapy in terms of progression-free survival (PFS) and overall survival (OS), whereas in CheckMate-026, nivolumab (Opdivo) failed to improve PFS compared with chemotherapy.
Read Article
Death Rates Unaffected by Treatment Choice for Patients with Localized Prostate Cancer
By
Alice Goodman
Prostate Cancer
,
Solid Tumors
October 2016, Vol 7, No 9
Read Article
Page 4 of 16
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
3.
Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma